Qin, Huiling
Tan, Yan
Diao, Lei
Hui, Ai-Min
Wu, Zhuli
Zhou, Yongchun
Sun, Juan
Xiang, Xiao
Qiu, Jingjun
Funding for this research was provided by:
Shanghai Fosun Pharmaceutical Development Co., Ltd and Wanbang Biopharmaceuticals
Article History
Accepted: 2 October 2023
First Online: 7 November 2023
Declarations
:
: Yan Tan, Lei Diao, Zhuli Wu, Juan Sun, Xiao Xiang and Jingjun Qiu, are employees of Shanghai Fosun Pharmaceutical Industrial Development CO., Ltd. Yongchun Zhou is an employee of Wanbang Biopharmaceuticals. Ai-Min Hui is an employee of EnCureGen Pharma. Huiling Qin and Wei Hu have no conflicts of interest to declare.
: The protocol for this study was approved by the Ethics Review Board at The Second Hospital of Anhui Medical University (approval number: CTR20212829). All subjects provided written, informed consent before entering this study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Not applicable.